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ABSTRACT
Abiraterone acetate is the first second-line
hormonal agent proven to improve survival in
metastatic castration-resistant prostate cancer.
It selectively inhibits cytochrome P450 17
(CYP17) a-hydroxylase and cytochrome17,20
(C17,20)-lyase, which are enzymes critical for
androgen synthesis. Abiraterone acetate was
initially approved in the United States in 2011
after demonstrating a 4-month survival benefit
in docetaxel-refractory metastatic prostate
cancer. The FDA recently expanded its
indication for use in the pre-chemotherapy
setting after it elicited significant delays in
disease progression and a strong trend for
increased overall survival in phase III studies.
Ongoing investigations of abiraterone are
evaluating its efficacy in earlier disease states,
exploring its synergy in combination with other
therapeutic agents, and assessing the necessity
for administration of concurrent steroids and
gonadal suppression. The identification and
development of predictive biomarkers will
optimize the incorporation of abiraterone into
the management of advanced prostate cancer.
Keywords: Abiraterone; Androgen
dependence; Castration-resistant prostate
cancer; CYP17 inhibitor; Oncology; Prostate
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INTRODUCTION
The last 3 years have witnessed tremendous
advances in the treatment of castration-
resistant prostate cancer (CRPC), a disease
from which approximately 30,000 men die
annually in the United States [1]. After a
6-year dearth of survival-improving therapies,
five agents have emerged that improve survival
in CRPC. In 2010, the first cancer vaccine,
sipuleucel-T, and a second-generation taxane,
cabazitaxel, were approved [2, 3]. 2011 brought
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abiraterone acetate (Zytiga, Janssen Biotech,
Inc, Horsham, PA, USA), a first-in-class, highly
potent and tolerable androgen biosynthesis
inhibitor, which elicited a median 4-month
survival benefit in docetaxel-refractory patients
[4, 5]. 2012 showcased the survival-improving
abilities of both enzalutamide (formerly
MDV3100), an agent engineered to block both
the binding of androgens to the androgen
receptor (AR) and nuclear transport of AR, and
a novel bone metastasis-homing
radiotherapeutic agent, radium-223 chloride
(formerly Alpharadin, Algeta US, LLC,
Cambridge, MA, USA and Bayer, Pittsburgh,
PA, USA) [6–8]. Abiraterone acetate moved to
the pre-chemotherapy setting after
demonstrating improvements in progression-
free survival (PFS) and overall survival (OS)
when compared to prednisone/placebo [9].
Finally, the introduction of a novel bone-
protective agent, denosumab, which delays
time to skeletal metastasis and skeletal-related
events in the ‘pre-abiraterone/enzalutamide’
era, has complemented these survival-
enhancing cytotoxic and hormonal therapies
[10, 11].
Prostate cancer is a very heterogeneous
disease, which can range from slowly growing,
indolent disease that would never induce death,
to aggressive variants that necessitate
immediate initiation of systemic therapy to
control disease progression and symptoms.
Multiple lines of evidence have shown that
androgens drive the growth and survival of
prostate cancer cells [12, 13]. The pioneering
work of Charles Huggins and colleagues [14] in
the 1940s formed the cornerstone of the initial
treatment for advanced prostate cancer, which
is directed at ablating androgen synthesis
pathways either by medical or surgical
castration. While initially immensely effective
in most patients, within 2–3 years, almost all
patients with metastatic disease develop
insensitivity to first-line androgen deprivation
therapy (ADT) despite castrate levels of serum
testosterone, a disease state now referred to as
CRPC or, in the past, hormone-refractory or
androgen-independent disease [15, 16].
While the expanding treatment
armamentarium is encouraging, CRPC remains
lethal and the individual survival benefits of
even the newest agents remain modest at
2–5 months [2–6, 8, 17]. Further, the taxanes
have cumulative toxicities, and the
immunotherapeutic sipuleucel-T is labor
intensive, and elicits few tangible prostate-
specific antigen (PSA) or radiologic responses
to decrease patient anxiety and control
symptoms [3, 17]. Moreover, all of the new
agents are costly. Administration of second-line
hormonal therapies is often pursued prior to
chemotherapy given their enhanced tolerability
and with the rationale of targeting the
theoretical persistent dependence on AR
signaling, even after castration resistance has
been proven clinically. The PSA responses
achieved by the adrenal steroid biosynthesis
inhibitor, ketoconazole, and second-line
antiandrogens, like nilutamide, provide
evidence for this continued reliance on
androgens in CRPC [18–21]. The more
substantial declines in PSA and improvements
in survival with abiraterone acetate and
enzalutamide validate this principle.
This review will focus on abiraterone acetate,
which is a selective inhibitor of cytochrome
P450 17 (CYP17) a-hydroxylase and
cytochrome17,20 (C17,20)-lyase, enzymes, which
are critical to androgen synthesis (Fig. 1).
Abiraterone acetate elicits significant
antitumor activity in CRPC. It induces PSA
declines of C50% in 29–62% of patients,
achieves OS benefits in both docetaxel-
refractory and chemotherapy-naı¨ve patients,
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delays and reduces skeletal-related events, and
palliates pain [4, 9] (Table 1). This multi-faceted
efficacy, along with an excellent safety and
tolerability profile compared to chemotherapy,
positions abiraterone acetate as an agent that
enhances patient outcomes and quality of life in
the pre-chemotherapy setting, and it may be
incorporated as part of novel treatment
approaches in earlier disease states. We will
detail the development of abiraterone acetate,
consider its placement in the expanding CRPC
treatment armamentarium, and discuss future
strategies to enhance its effectiveness.
CASTRATION-RESISTANT
PROSTATE CANCER
Phase III trials completed in the 1990s reported
a median OS of 16–18 months from the start of
docetaxel in CRPC. In contrast, contemporary
phase III trials of androgen axis inhibitors, such
as abiraterone acetate and enzalutamide, given
after docetaxel therapy have reported a median
survival of 15–18 months [4, 6]. This
improvement in median survival is related to
both a shift toward earlier initiation of
treatment and a real improvement in survival
elicited by these new agents.
The drivers behind the progression to CRPC
are multifactorial but can be attributed to
persistence of androgens from non-gonadal
sources and intratumoral AR signaling. Rarer
transformation to true androgen axis
independence can also occur [22]. In the
eugonadal state, the testes synthesize 80% of
the body’s testosterone, but another 20% is
produced by the adrenal glands, and in CRPC,
the tumor itself can produce intracrine
androgens [23]. Tissue studies in healthy
volunteers have demonstrated that despite
Fig. 1 Androgen axis: physiologic pathways and possible tumor bypass pathway for the production of testosterone. ACTH
adrenocorticotropic hormone, DHEA dihydroepiandrostendione, DHT dihydrotestosterone, Testo testosterone
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induction of castrate levels of serum
testosterone with gonadotropin-releasing
hormone (GnRH) agonists, intraprostatic tissue
androgen levels may only decline by
approximately 30%, leaving sufficient ligand
to stimulate the AR [24]. In hormone-sensitive
prostate cancer patients, Mostaghel and
colleagues [25] examined the effects of short-
term (1–9 months) castration on intraprostatic
androgen levels and the expression of
androgen-regulated genes. They found
significant heterogeneity between serum and
prostate tissue levels of testosterone and other
markers of androgen regulation. While
castration decreased intraprostatic tissue
androgens by 75%, not all androgen-regulated
genes, such as TMPRSS2 and PSA, were
suppressed [25]. Additionally, these
investigators demonstrated that the level of
tissue testosterone in metastatic CRPC is
significantly higher than levels even from
eugonadal prostate controls. The authors
concluded that the effects of medical
castration, as assessed by serum testosterone,
did not correspond with the degree of androgen
depletion occurring in the prostate tissue or
CRPC metastases [25]. This persistent repository
of tumor androgen enables adaptive AR-related
resistance mechanisms to develop. Together,
these studies bring into question our historical
use of serum testosterone as a surrogate marker
for tumor androgen activity. Identification of
better proxies for tumor androgen depletion
and more effective strategies to neutralize non-
gonadal androgen sources is imperative.
AR-related mechanisms for tumor growth in
CRPC include: AR amplification; AR splice
variants leading to constitutively active
receptors; mutations leading to promiscuous
AR activation by weak androgens, other steroid
hormones, and even traditional antagonists,
such as antiandrogens; changes in AR co-
regulatory proteins; and synthesis of tumor
androgens [26–30]. Increased expression of
genes converting adrenal androgens or tissue
precursors, such as cholesterol to testosterone,
has been observed in CRPC [28]. Tumoral
androgen production may even stem from
variant synthetic pathways. Work by the
Sharifi Laboratory demonstrates that contrary
to conventional thought, the dominant route of
tumoral dihydrotestosterone (DHT) synthesis in
CRPC actually bypasses testosterone and
instead, acts through 5a-reduction of
androstenedione [31].
The AR regulates PSA expression, and an
elevated PSA level is usually the first
manifestation of CRPC. An elevated PSA may
reflect renewed AR activation or ongoing
transcription of androgen-AR-regulated genes,
which may primarily stimulate or co-stimulate
cancer growth [32–34]. This sign of persistent
intratumoral AR signaling in CRPC suggests
potential sensitivity to more intensive
androgen deprivation, which has been
evidenced by the \56% PSA response rates
with older-generation, second-line hormonal
agents, such as ketoconazole and the AR
antagonists, bicalutamide (daily dose of
50–200 mg), flutamide, and nilutamide [18–20,
35, 36]. The persistence of serum PSA and the
responses seen with older, secondary hormonal
blockade, combined with a desire to develop less
toxic and more selective agents than existing
chemotherapeutics has driven the development
of the latest generation of AR and androgen
biosynthesis inhibitors. These agents include
the ligand synthesis inhibitors, abiraterone
acetate and orteronel (TAK-700), the receptor
signaling inhibitors, enzalutamide and ARN509,
as well as the combined receptor and androgen
synthesis inhibitor, galeterone (TOK-001).





Abiraterone acetate is the prodrug of
abiraterone. It acts through irreversible CYP17
inhibition, but is more targeted and potent than
the older generation, non-specific CYP
inhibitor, ketoconazole. Its superior efficacy
and tolerability reflect this greater selectivity
against CYP17, making it significantly more
potent than ketoconazole [23, 37]. Abiraterone
acetate’s inhibition of CYP17 a-hydroxylase and
C17,20-lyase triggers a cascade of predictable
endocrinologic changes (Fig. 1). CYP lyase
inhibition results in a reduction of androgens
downstream of pregnenolone, including
dihydroepiandrostendione (DHEA),
androstenedione, testosterone, and DHT [23].
The decreased conversion of pregnenolone to
17 OH-pregnenolone and of progesterone to
17a-OH progesterone translates into increased
levels of pregnenolone and progesterone.
However, as 17 OH-pregnenolone and 17-OH
progesterone are its substrates, cortisol levels
subsequently decrease. The reduction in cortisol
activates a negative feedback loop, stimulating
adrenocorticotropic hormone (ACTH)
production. There is potential for resultant
mineralocorticoid excess (ME), which is a
possible dose-limiting toxicity of abiraterone
acetate in some patients. However, the
incidence of ME is generally abrogated by
concomitant administration of prednisone (or
dexamethasone) or aldosterone antagonists,
such as eplerenone or even spironolactone
[38]. The most common symptoms of ME
observed with abiraterone acetate
administration are hypokalemia, hypertension,
and edema, and were seen in 17, 10–22, and
28–31% of patients, respectively, in the phase
III studies [4, 9].
In contrast to the prevention of ligand
binding that occurs with AR antagonists, or
the singular inhibition of gonadal androgen
synthesis that occurs with GnRH agonists or
antagonists, abiraterone acetate’s effects are
wide-ranging. All androgen synthesis
pathways rely on CYP17; thus, abiraterone
acetate disturbs adrenal, gonadal, and
intratumoral androgen production [23].
Created by chemists at the Royal Marsden
Hospital in the UK, abiraterone acetate’s
development for the treatment of prostate
cancer was delayed for 10 years due to safety
concerns at the time over the associated
adrenal insufficiency and because of a
disinterest in secondary hormonal blockade as
a viable therapeutic maneuver for prostate
cancer [38]. The investigators, de Bono and
Attard [32, 39], resurrected interest in the
compound and initiated phase I testing in a
group of asymptomatic, chemotherapy-naı¨ve
patients with good performance status. The
initial studies provided important insight into
abiraterone acetate’s therapeutic effects and
toxicity profile in the absence of concomitant
steroids.
Abiraterone acetate was initially studied in
the chemotherapy-naı¨ve CRPC setting [32, 39–
41]. In the first phase I/II trial, de Bono and
Attard evaluated abiraterone as monotherapy
without concomitant steroids in 54 patients
[32]. Continued administration of a luteinizing
hormone-releasing hormone (LHRH) agonist
was mandated to prevent any compensatory
luteinizing hormone (LH) surge and
testosterone production that might overwhelm
abiraterone acetate’s CYP17 blockade [32, 42].
While up to 2,000 mg per day was found to be
tolerable, a plateau in pharmacodynamic effect
advocated for 1,000 mg as the recommended
monotherapy dose [39]. Notably, abiraterone
also induced near-undetectable levels of
732 Adv Ther (2013) 30:727–747
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circulating androgens, such as serum
testosterone, DHEA-sulfate, and DHT, but
increased levels of mineralocorticoids, such as
deoxycorticosterone and aldosterone. In fact,
the development of exquisitely sensitive assays,
such as liquid chromatography tandem mass
spectrometry, was required to measure such low
levels of androgen [39]. Despite the increased
levels of mineralocorticoids, no symptoms of
ME were reported. Of the 42 patients enrolled in
this phase II trial who were treated with
abiraterone acetate 1,000 mg daily, 67%
achieved a PSA decline of C50%. In the
24 patients with measurable disease by
Response Evaluation Criteria in Solid Tumors
(RECIST), 38% experienced partial responses.
The median time to PSA progression (TTPP) was
225 days [95% confidence interval (CI),
162–287 days]. As per protocol, dexamethasone
(0.5 mg daily) was added at the time of
progression in order to evaluate whether
steroids could reverse the possible effects of
excess ACTH and upstream steroids. The latter
have been implicated in activating a mutated or
promiscuous androgen receptor, if present [43,
44]. The addition of dexamethasone resulted in
a subsequent PSA decline ranging from 36–99%
in 4 of 15 patients, suggesting re-sensitization to
abiraterone acetate. The duration of response to
the dexamethasone–abiraterone acetate
combination ranged from C49 to [348 days;
all responses were ongoing at the time of
publication of the results. Higher pre-treatment
androgen and estradiol levels were associated
with an increased probability of PSA response
and prolonged TTPP [32]. These findings may
indicate that these serum hormone levels are
predictive biomarkers that could optimize the
selection of patients who would be most likely
to benefit from abiraterone acetate therapy.
Targeting a somewhat less advanced disease
subset, a concurrent phase I trial of abiraterone
acetate was performed in 33 patients with
progressive CRPC, as evidenced by an elevated
PSA level with or without radiologic evidence of
distant metastasis [41]. In addition, this trial
differentiated itself from the initial Attard trial
[39] by enrolling patients who had received
prior treatment with ketoconazole. This
relaxation of eligibility criteria permitted
important data capture on abiraterone
acetate’s efficacy in a disease state of unmet
need—biochemical relapse—and addressed the
clinically relevant question of whether past
ketoconazole administration conferred
resistance to abiraterone acetate, given their
similar mechanisms of action through CYP
inhibition. However, the limitation of this
inclusiveness was a resultant heterogeneous
patient population. As expected, the majority
(70%) of patients had bony metastases while
only 18% had visceral metastases [41]. A smaller
proportion (9%) of patients had evidence of
biochemical recurrence, or locally advanced
disease with no signs of distant metastasis on
imaging. More than half (58%) of the patients
had received prior ketoconazole with the
majority (84%) having ketoconazole-sensitive
disease, as evidenced by PSA declines of C50%
during ketoconazole administration. Based on
data from the Attard study, including clinical
responses, maximization of anticipated
endocrinologic effects, and its favorable safety
profile, dose escalation of abiraterone acetate
was stopped at 1,000 mg/day. In the entire
cohort, decline of PSA levels at week 12
occurred in 55% of patients, including nine
who had received prior ketoconazole. The
median time to PSA progression was 234 days,
likely reflecting the earlier disease state of
patients compared with those in the Attard
trial. Median duration of therapy was
15 months. Responses with abiraterone acetate
were observed not only in patients who had not
Adv Ther (2013) 30:727–747 733
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responded (33%) to ketoconazole, but also in
those who had initially responded but
eventually progressed on ketoconazole (46%)
[41]. These latter results indicate a lack of cross-
resistance between the two agents.
Confirming the preliminary efficacy
observed in the phase I studies, a subsequent
phase II trial evaluated abiraterone acetate plus
prednisone in 33 patients with progressive,
metastatic, CRPC who were both
chemotherapy- and ketoconazole-naı¨ve [40].
The great majority (79%) of patients had a
decline in PSA levels of C50%. Disease control
was remarkably durable for this population,
with a median time to PSA progression of
16.3 months. Interestingly, discordant bone
scans occurred in nearly half (11/23) of the
patients who were thought to be responding to
abiraterone acetate by PSA criteria [40]. These
discordant responses were later confirmed to be
flare phenomena, since the lesions improved on
subsequent scans. Flare phenomenon occurs
when, despite other signs of clinical response
such as PSA decline, bone lesions appear more
intense on bone scan. The ‘worsening’ of the
lesion actually reflects treatment response, but
may be misinterpreted as disease progression by
the reviewer [40]. The requirement by Ryan and
colleagues for a confirmatory scan highlights
the potential for this phenomenon to occur
with abiraterone acetate treatment. It may
occur in up to 50% of cases, which emphasizes
the importance of confirmatory scans prior to
therapy discontinuation with this agent [40].
Evolving imaging techniques with novel tracers
and the incorporation of serum and urine
markers of bone turnover, such as bone-
specific alkaline phosphatase, may further
distinguish flare effects due to treatment
response from those of disease progression.
The two phase II trials evaluating abiraterone
acetate in CRPC reported response rates of
36–51% and TTPP of 168 days, and provided
the basis for the first phase III study in the
docetaxel-refractory CRPC setting [45, 46]. The
primary endpoint of the first phase III study was
OS. Secondary endpoints included time to PSA
progression, PFS according to radiologic
findings based on pre-specified criteria, and
the PSA response rate [4]. Patients were
randomized in a 2:1 fashion to receive either
abiraterone acetate/prednisone (oral
abiraterone 1,000 mg once daily in
combination with oral prednisone 5 mg twice
daily, n = 797) or placebo/prednisone (oral
placebo once daily in combination with oral
prednisone 5 mg twice daily, n = 398). The
majority of patients had an Eastern
Cooperative Oncology Group (ECOG)
performance status of 0 or 1. Ninety percent of
patients had bony metastases and 30% had
visceral involvement. While all patients had
received at least one line of docetaxel therapy,
approximately 30% of patients had received two
prior lines of chemotherapy. Patients who had
received prior ketoconazole therapy for prostate
cancer, or had neuroendocrine differentiation
of their prostate cancer were excluded [4].
At the time of interim analysis, abiraterone
acetate/prednisone induced significantly longer
OS compared to prednisone/placebo [14.8 vs.
10.9 months, respectively, hazard ratio (HR)
0.65; 95% CI 0.54–0.77; P\0.001] [4]. Median
follow-up was 12.8 months. All secondary
endpoints favored the abiraterone acetate arm,
including time to PSA progression (10.2 vs.
6.6 months, respectively; P\0.001), PFS (5.6 vs.
3.6 months, respectively; P\0.001), and PSA
response rate (29% vs. 6%, respectively;
P\0.001). The final analysis of the study
occurred before unblinding and subsequent
patient crossover from placebo to abiraterone
acetate [5]. After 775 of the pre-specified
799 death events and a median 20.2 months of
734 Adv Ther (2013) 30:727–747
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follow-up, median OS was 15.8 months versus
11.2 months for the abiraterone arm compared
with the placebo arm, respectively (HR 0.74,
95% CI 0.64–0.86; P\0.0001). Median time to
PSA progression was 8.5 months, median
radiologic PFS was 5.6 months, and 29.5% of
patients had a PSA response on the abiraterone
acetate arm; all were statistically significantly
increased compared with the corresponding
results in the placebo arm, and were similar to
the initial efficacy analysis [5].
The most common toxicities attributed to
abiraterone acetate in the phase III, post-
docetaxel study were related to testosterone
depletion and ME, such as fluid retention,
hypertension, and hypokalemia. The most
common grade 3–4 events occurred with
similar frequency in both cohorts: fatigue
(9–10%), anemia (8%), back pain (7% vs.
10%), and bone pain (6% vs. 8%) [5]. No new
safety concerns were identified in the phase III
study. Importantly, fewer patients discontinued
treatment because of toxicity in the abiraterone
acetate group compared to the control group
(13% vs. 18%, respectively) [5].
The phase III, post-docetaxel abiraterone
acetate trial was also notable for its integrated
correlative assessments of quality of life, fatigue,
and pain. These factors are important
considerations, as patients with CRPC can
range from being asymptomatic to having
significant debilitating bony pain or
multifactorial fatigue related to anemia, past
anti-cancer treatment, or cancer progression.
Sternberg and colleagues incorporated into the
phase III abiraterone study ‘The Brief Fatigue
Inventory’, a validated fatigue assessment tool
as an outcome measure [47]. In patients who
reported clinically significant fatigue at study
initiation, abiraterone acetate achieved
clinically meaningful benefits compared to
prednisone alone. It elicited significant
reductions in intensity of fatigue, improved
fatigue interference, and faster reduction in
fatigue intensity [47]. To assess whether pain
and skeletal-related events were reduced with
abiraterone acetate, Logothetis and colleagues
[48] issued a ‘Brief Pain Inventory’
questionnaire at baseline, day 15 of cycle 1,
and day 1 of each cycle thereafter. In patients
with substantial pain at baseline, abiraterone
acetate achieved significantly greater
improvements in pain palliation, faster time to
pain reduction, and interference with daily
activities than steroids alone. Abiraterone
acetate meaningfully impacted skeletal-related
events, defined as pathologic fracture, spinal
cord compression, need for palliative radiation
to bone, or surgery to the bone. In the entire
study population, abiraterone acetate
prolonged the median time to occurrence of
first skeletal-related event by 5 months (25 vs.
20 months, P = 0.001) [48].
Based on a 4-month survival benefit, the FDA
granted approval of abiraterone acetate in April
2011 [4]. Given the need to improve tolerability
of therapeutic agents and preference to avoid
chemotherapy, abiraterone acetate’s outcomes
in chemotherapy-naı¨ve patients were highly
anticipated. Ryan and colleagues executed a
phase III study in asymptomatic or only mildly
symptomatic patients with progressive,
chemotherapy-naı¨ve metastatic CRPC disease
[9]. This multicenter, international trial
randomized 1,088 patients in a 1:1 fashion to
receive either abiraterone acetate 1,000 mg
daily in combination with oral prednisone
5 mg twice daily (n = 546) or oral placebo with
prednisone 5 mg twice daily (n = 542). The co-
primary endpoints were radiographic PFS and
OS. Secondary endpoints included time to
opiate use for cancer-related pain, time to
initiation of chemotherapy, time to
deterioration in ECOG performance status,
Adv Ther (2013) 30:727–747 735
123
and time to PSA progression [9]. A modified
version of the Prostate Cancer Working Group 2
criteria was used to define progressive disease on
bone scan [49]. This trial was noteworthy for
being the first phase III study in prostate cancer
since the mitoxantrone trials in the late 1990s
in which the FDA allowed a primary endpoint
other than OS, and may pave the way to testing
new compounds at earlier disease stages [50,
51].
In the pre-docetaxel, abiraterone acetate
phase III trial, the two arms were well
balanced in terms of median age, time from
diagnosis, baseline PSA, testosterone, levels of
alkaline phosphatase, hemoglobin and lactate
dehydrogenase (LDH), and the extent of bone
and visceral disease as well as baseline pain [52].
The median duration of follow-up was
22.2 months. The study was halted early after
a statistically significant improvement in the
primary endpoint of radiographic PFS (rPFS) was
observed at the second interim analysis. The
median PFS had not been reached in the
abiraterone acetate arm but was 8.3 months in
the placebo arm (HR 0.43; 95% CI 0.35–0.52;
P\0.0001) [52]. At the subsequent analysis, the
combination of abiraterone acetate–prednisone
elicited a median PFS of 16.5 months compared
to 8.3 months with prednisone alone (HR 0.53;
95% CI 0.45–0.62; P\0.001) [9]. While it did
not cross the pre-specified efficacy boundary,
there was a robust trend to improvement in OS
with abiraterone acetate–prednisone compared
to prednisone alone (median not reached vs.
27.2 months; HR 0.75; 95% CI 0.61–0.93;
P = 0.01). Subgroup analyses of baseline
performance status, pain level, presence of
bone metastasis, age, PSA, LDH and alkaline
phosphatase levels, and region all favored an
rPFS and OS benefit for treatment with
abiraterone acetate [9]. rPFS positively
correlated with OS (correlation coefficient
0.72). This relatively strong correlation
suggests that rPFS may be a good surrogate for
OS in patients receiving abiraterone acetate, but
this requires further validation.
Statistically significant PSA declines of C50%
were elicited in 62% of patients on abiraterone
acetate compared to 24% of patients on
prednisone, and objective RECIST responses in
36% vs. 16% of patients in the study arms,
respectively [9]. Although significantly lower,
the 24% rate of PSA declines of C50%, and the
objective response rate of 16% with prednisone
alone confirms its single-agent activity. All
secondary endpoints, such as time to the need
for opiate use for cancer-related pain (not
reached vs. 23.7 months) and time to the
initiation of cytotoxic chemotherapy
(25.2 months vs. 16.8 months) were
statistically significantly improved with
abiraterone acetate compared with prednisone.
Patient-reported outcomes also favored the
investigational agent. The statistically
significant delays in disease progression, strong
trend towards increased OS, the lack of any
concerning new toxicities, and uniformly
positive secondary endpoints all favored
abiraterone acetate’s extended approval and
use in CRPC patients who have not received
prior chemotherapy [9]. Ultimately, on
December 10, 2012, the FDA expanded
abiraterone acetate’s indication to include
chemotherapy-naı¨ve CRPC patients [53].
While not reported in Ryan’s published
manuscript, the FDA announcement conveyed
that the median OS for those in the abiraterone
acetate arm was 35.3 months compared with
30.1 months for those receiving placebo (HR
0.79; 95% CI 0.66–0.96) [53]. Despite what we
assert is a clinically significant 5-month benefit
for abiraterone acetate, this difference was not
statistically significant according to the pre-
specified O’Brien–Fleming boundary of
736 Adv Ther (2013) 30:727–747
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P B 0.001 [53]. The results of this trial and its
approval are historic as no previous non-
cytotoxic, non-chemotherapy agent has
significantly impacted PFS or OS in
chemotherapy-naı¨ve CRPC patients while
maintaining or improving quality of life for
our patients.
Importantly, given the relatively fit and often
asymptomatic population, no new safety signals
were seen despite the longer duration of
administration in this study (median
16 months) compared to the registration trial
in docetaxel-refractory CRPC (median
8 months; A. Molina, Johnson and Johnson,
personal communication). The frequency of
treatment discontinuation due to drug toxicity
was similar in the two arms. The majority halted
study treatment for progressive disease, while
only 7% were discontinued due to toxicity in the
abiraterone acetate arm, and 5% in the placebo
arm [52]. Abiraterone acetate induced a higher
rate of all grade fatigue (39%), arthralgias (28%),
peripheral edema (28%), and hepatotoxicity
(11–12%; \1% grade 3 or more) than
prednisone [9]. As expected, other side effects
related to ME, such as hypertension (22%) and
hypokalemia (17%), were more common with
abiraterone acetate than with prednisone; most
were low grade. Hepatotoxicity generally
occurred within the first 3 months of
treatment and did not contribute to any
deaths. Non-hypertensive cardiac events, of
which there was a slight increase in the
abiraterone acetate arm compared with the
prednisone arm (19% vs. 16%, respectively;
grade 3 or 4: 6% vs. 3%, respectively), tended
to have a later onset ([3 months). These
incidents included myocardial infarction, heart
failure, and arrhythmias. Finally, as per the FDA
notice, adrenal insufficiency was observed in
0.5% of patients on abiraterone acetate vs. 0.2%
of patients on placebo [53].
In summary, clinicians should be vigilant of
the rare but real possibility of developing
adrenal insufficiency with abiraterone acetate
treatment, and the more common and easily
treatable symptoms of ME. The long-term
toxicities of steroid use, which are especially
germane in a longer-living, chemotherapy-
naı¨ve population, are also an important
consideration. While prednisone 5 mg twice
daily is the standard regimen used with
abiraterone acetate and studied in the phase
III setting, de Bono and colleagues initially
favored dexamethasone 0.5 mg once daily due
to its long half-life and lack of mineralocortical
effects, and used it with satisfactory results [32].
There has been no investigation into which
patients actually need steroids and at what
dosage to prevent ME. Studies are ongoing to
determine whether lower doses of steroid, or
administration of steroids or an aldosterone
antagonist at first signs of toxicity achieve
similar effectiveness while optimizing safety
and quality of life. Likewise, the need for
concurrent GnRH axis inhibition to prevent a
potential LH surge is being investigated; LH
surge was observed in two of three non-castrate
males given abiraterone, although it is not
known whether this effect would be observed
in older men with a history of long-term
castration [42].
Predictive Biomarkers
and Pharmacodynamic Effects on Tissue
In addition to evaluating their effects on serum
androgen and steroid levels, several
investigators have attempted to look at the
pharmacodynamic consequences of drugs in
tumor tissue in order to better elucidate
mechanisms of drug response and patterns of
resistance, and to identify predictive signatures.
In an informative translational study of
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57 patients with bone-metastatic CRPC treated
with abiraterone acetate, Efstathiou and
colleagues [54] measured androgen signaling in
bone marrow-infiltrating CRPC, as well as
testosterone levels in serum and marrow
aspirate, and correlated these endpoints with
clinical outcome. Patients underwent transiliac
bone marrow aspirate and biopsies prior to
starting treatment with standard-dose
abiraterone acetate, at week 8 on therapy, and
at the end of this observational study.
Corresponding blood plasma and serum levels
were collected within 2 h of the biopsy.
Immunohistochemistry (IHC) was used to
assess AR and CYP17 expression. Tumor-
infiltrating bone marrow samples were
obtained in 27 patients at baseline and in
30 patients at any time point. A quarter of
patients (14/56) had primary drug-resistant
disease [54]. Testosterone concentrations in the
marrow aspirate were higher than in blood in
7/42 patients. This study ultimately confirmed
that marrow aspirate androgen depletion was
generally achieved by 8 weeks, and remained
depleted at cessation of therapy. A strong
correlation existed between pre-treatment
circulating levels and microenvironment (non-
tissue) marrow aspirate testosterone levels
(Pearson’s r = 0.91) [54].
The evaluation of nuclear AR and
cytoplasmic CYP17 expression in this work
unveiled a potential predictive signature for
abiraterone acetate response [54]. AR expression
by IHC was frequently higher at baseline than
on treatment, while pre-treatment CYP17
expression was more heterogeneous.
Homogenous intense expression of nuclear AR
in combination with C10% CYP17 tumor
expression correlated with a longer time to
treatment discontinuation ([4 months,
P\0.001) [54]. In the cohort of 25 patients
whose tumors met these criteria, only one
patient had primary drug-resistant disease.
Conversely, only two patients whose tumor
did not have this expression signature had a
long-term response. One patient whose tumor
lacked one or both of these findings had
primary resistant disease (n = 10), indicating
that patients without this molecular profile
may not benefit from abiraterone acetate [54].
Higher pre-treatment CYP17 tumor expression
also correlated with increased testosterone
expression in the marrow aspirate, suggesting
that these tumors are capable of intratumoral
androgen synthesis, which may drive their
disease resistance [54]. This work establishes
the feasibility and potential value of sampling
bone metastasis to explore mechanisms of
resistance and to demonstrate that drugs are
achieving their on-target effects. It further
substantiates that persistent androgen
signaling in CRPC tumors is functionally
significant and confirms that abiraterone
acetate effectively depletes testosterone in
blood and bone marrow aspirates. This study
validated Attard and colleagues’ findings [39]
that abiraterone acetate reduced plasma
testosterone and DHT levels to undetectable
levels, but was the first to prospectively
establish that it also reduced marrow aspirate
testosterone and DHT concentrations to less-
than-picogram-per-milliliter amounts, and that
the levels remained suppressed at progression.
Men with localized but high-risk prostate
cancer have suboptimal cure rates with
prostatectomy [55]. Neoadjuvant trials of
agents, such as abiraterone acetate, that can
achieve intense androgen deprivation are a
logical approach to improve outcomes in these
men and permit pharmacodynamic
investigation of the mechanisms of response
and resistance. Taplin and colleagues
executed the first randomized, neoadjuvant
study investigating abiraterone acetate’s
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pharmacodynamic effects in high-risk patients
fit for prostatectomy [56]. In this multi-
institutional, phase II study, patients were
initially randomized to leuprolide or
leuprolide/abiraterone acetate/prednisone
(5 mg daily) for 3 months (Fig. 2) [56]. The
primary endpoint of the trial was the
evaluation of prostate testosterone and DHT
levels after 3 months of therapy. After the first
3 months of therapy, all patients were treated
with an additional 3 months of leuprolide/
abiraterone acetate/prednisone (5 mg daily).
Thus, one cohort received 6 months of
abiraterone acetate and the other group
received 3 months of abiraterone acetate, but
all patients received 6 months of ADT in total
[56]. All participants had prostatectomy after
6 months of ADT. Eligibility targeted high-risk
patients and required that patients had
positive biopsies in three or more cores,
Gleason score C7 (4 ? 3), stage T3 disease,
PSA C20 ng/mL, or a PSA velocity of [2 ng/
mL/year [56]. Fifty-eight patients were accrued
over 18 months. Secondary endpoints
included pathologic staging at prostatectomy,
PSA response, and assessment of androgen
receptor signaling. Publication of the results
of this work is pending, and only data
presented at the 2012 American Society of
Clinical Oncology (ASCO) Annual Meeting is
described here [56].
Longer (6-month) compared with shorter
(3-month) abiraterone acetate administration
achieved a greater percentage of pathologic
complete response (CR) (10% vs. 4%,
respectively), near pathologic CR (24% vs.
11%, respectively), and any disease shrinkage,
as assessed by a composite endpoint of true
pathologic CR plus near CR (15% vs. 34%,
respectively) [56]. The primary endpoint was
to induce a significant reduction in prostate
tumor androgen levels (DHT and DHEA) at the
12-week mark and was realized with the
combination therapy compared to leuprolide
alone (P\0.0001). In the group who started
abiraterone acetate after 12 weeks of leuprolide
monotherapy, the addition of abiraterone
acetate induced a statistically significant
decrease in DHT and DHEA levels at
24 weeks compared to their pre-abiraterone
acetate baseline at 12 weeks (P = 0.0004) [56].
Similar decreases were seen with
Fig. 2 Randomized, phase II neoadjuvant study of abira-
terone acetate, leuprolide, and prednisone in newly
diagnosed intermediate and high-risk patients with prostate
cancer undergoing radical prostatectomy (N = 58). AA
abiraterone acetate, AR androgen receptor, CaP prostate
cancer, LHRHa leuprolide acetate, Pred prednisone, PSA
prostate-speciﬁc antigen, qd once daily, R randomize
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androstenedione and, to a lesser degree, with
testosterone. As expected, given the inhibition
of CYP17 a-hydroxylase conversion of
pregnenolone and progesterone to their 17-a
hydroxy derivatives, pregnenolone and
progesterone levels were higher in prostate
tissue from abiraterone acetate-treated patients
as compared to the corresponding levels from
patients in the leuprolide monotherapy arm at
12 weeks [56].
The safety of neoadjuvant abiraterone
acetate administration is paramount given that
patients are generally asymptomatic with
excellent quality of life. No new safety signals
were identified during this study and the
toxicity profile was consistent with past phase
III data in the chemotherapy-refractory setting
[4, 56]. Grade 3 liver function abnormalities did
not increase significantly with the longer
duration of dosing: 7.1% vs. 10% with 12- and
24-week dosing of abiraterone acetate,
respectively [56].
Past trials of ADT with an LHRH agonist
administered neoadjuvant to prostatectomy did
not alter the PSA relapse rate and this approach
has been abandoned from clinical practice [57,
58]. The current availability of more effective
ADT has renewed interest in the analysis of
combined systemic androgen deprivation with
surgery to increase cure rates in patients at high
risk of recurrence. At the Dana-Farber Cancer
Institute in the US, subsequent neoadjuvant
trials have been completed or are planned,
evaluating intense ADT neoadjuvant to
prostatectomy, assessing various compounds,
including combinations of abiraterone acetate,
enzalutamide, dutasteride, and ARN509. We
hope to determine the optimal combination
and duration of neoadjuvant ADT that will lead
to a randomized, phase III trial in high-risk
patients.
Resistance Mechanisms in the AR Pathway
As with all available therapies, eventual
resistance to abiraterone acetate occurs. Possible
mechanisms of resistance include either
reactivation of the AR or AR-independent
mechanisms [22, 27]. Nelson described four
molecular states for AR activation in prostate
cancer: (1) endocrine androgen dependent and
AR dependent; (2) intracrine androgen and AR
dependent; (3) androgen (ligand) independent
and AR dependent; and (4) ligand and AR
independent [22]. With its ability to inhibit
both host and tumoral testosterone production,
abiraterone acetate seems an ideal treatment for
ligand-dependent disease. But primary or
eventual on-therapy resistance ultimately
occurs, likely due to selective pressure from
ongoing therapy, which can lead to
transformation to a ligand-independent state
[22]. Alternative ligand-dependent mechanisms
include altered steroid biosynthesis in the tumor
microenvironment, increased ‘backdoor’
synthesis of DHT, and circumvention of
testosterone as the precursor [31, 54]. In the
first phase I study of abiraterone acetate where no
concomitant steroids were given, increased
presence of steroids upstream of CYP17 that
continued to drive AR signaling were a purported
source of resistance. The addition of steroids in
these patients temporarily reversed progression
in 4 of 15 patients [32].
A rising PSA often heralds progression on
abiraterone acetate. When this change occurs in
the setting of undetectable serum and tissue
androgens, it suggests persistent dependence on
AR signaling but ligand independence (Nelson
disease state 3) [22]. This transformation may be
driven by cross-talk with other signaling
pathways that can activate AR signaling in the
absence of androgens, and AR splice variants that
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create constitutively active ARs [22, 59, 60].
Possible ligand-independent mechanisms that
drive progression during treatment with
androgen biosynthesis inhibitors could include
loss of phosphatase and tensin homolog on
chromosome 10 (PTEN) loss, overexpression of
factors in the phosphatidylinositide 3-kinase/
protein kinase B (PI3-kinase/Akt) pathway,
overexpression of Bcl-2, c-Met, and others [54,
61–67].
Transformation to complete independence
from both androgen ligand and signaling
(Nelson disease state 4) is rare but should be
considered when PSA remains undetectable on
abiraterone acetate but the patient is clearly
progressing according to scans or symptoms.
We recommend treatment at this juncture with
novel, investigational, non-androgen-directed
strategies, such as chemotherapy. Conversely,
Nelson disease states 2 and 3 imply that
androgens or AR signaling continue to drive
tumor growth and thus, the tumors may remain
sensitive to further hormonal interventions.
FUTURE DIRECTIONS
Several innovative therapeutic strategies
incorporating abiraterone acetate are under
investigation or in development. Abiraterone
acetate’s safety profile makes it well suited to
combine with other agents in order to increase
its efficacy and target resistance pathways.
Additionally, its tolerability makes it an ideal
candidate to consider earlier in the course of
treatment, when patients are asymptomatic,
such as in the neoadjuvant, biochemical
recurrence (D0), hormone-naı¨ve, or pre-
chemotherapy metastatic settings.
The recent proof of abiraterone acetate’s
activity and safety in the chemotherapy-naı¨ve,
metastatic CRPC setting imparts confidence for
its safe investigation in earlier disease states.
The phase II Impact of Abiraterone Acetate in
Prostate-Specific Antigen (IMAAGEN) study will
explore its ability to effectively decrease PSA in
125 patients with biochemical progression on
GnRH monotherapy but with no evidence of
metastasis (ClinicalTrials.gov identifier:
NCT01314118). This disease state is an area of
unmet need where no standard therapy has
demonstrated a survival benefit.
One mechanism of persistent AR signaling in
CRPC is increased expression of enzymes, such
as AKR1C3 and SRD5A1, which are critical in
the regulation of testosterone and DHT
synthesis from precursor steroids [28].
Enzymes, such as SRD5A1, may lead to tumor
escape from CYP17 inhibition and GnRH axis
blockade. We recently completed a phase II
study in metastatic CPRC investigating the
addition of dutasteride, a dual SRD5A1/
SRD5A2 inhibitor, to abiraterone acetate
(ClinicalTrials.gov# NCT01393730). Prior
chemotherapy or any number of hormonal
therapies was permitted, but patients were
required to have a metastatic site amenable to
biopsy pre-treatment and at progression. The
primary objective was to analyze possible AR-
related mechanisms of abiraterone acetate
resistance. Clinical outcomes data are
maturing, and ongoing analysis of the tumor
specimens obtained prior to treatment and at
progression will evaluate the AR genetic
sequence (e.g., mutations, splice variants), AR-
regulated gene expression, tumor androgen
levels, and profiling of enzymes involved in
androgen synthesis and metabolism.
The AR antagonist and signaling inhibitor,
enzalutamide, is another avenue by which we
can target persistent AR signaling. Because
enzalutamide does not inhibit androgen
production, combining it with the potent
testosterone synthesis inhibitor, abiraterone
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acetate, makes sense in order to target all levels
of androgen production and signaling [68].
Leveraging their non-overlapping and
potentially synergistic effects, emerging studies
will assess the combinations of enzalutamide or
ARN509, an AR antagonist currently in
development, and abiraterone or TAK-700, a
CYP17 inhibitor currently in development, in a
variety of disease settings. Follow-up studies to
our abiraterone/leuprolide neoadjuvant trial are
planned in which we will escalate the intensity
of androgen deprivation and co-pathway
targeting. Within the United States Alliance
Clinical Trials co-operative group, a trial of
‘androgen annihilation’ for men with
biochemical relapse is in development.
Additionally, a co-operative group phase III
trial will randomize patients to enzalutamide
plus abiraterone acetate versus enzalutamide
monotherapy in metastatic CRPC patients prior
to chemotherapy (M. Morris, Memorial Sloan-
Kettering Cancer Center: personal
communication, Alliance meeting November
2012) [69].
The survival advantage of sipuleucel-T has
considerably challenged the dogma that
prostate cancer is not an immunotherapy-
sensitive tumor. Nesslinger and colleagues [70]
demonstrated that hormone therapy and
radiation could elicit antigen-specific immune
responses in the form of development of
autoantibodies to tumor-associated antigens.
Further, as reviewed by Aragon-Ching and
colleagues [71], there is evidence that ADT can
augment lymphopoiesis and enhance immune
responses to vaccines, restore thymopoiesis,
increase B cell development, and reverse
tolerance to prostate cancer antigens. Thus,
augmenting tertiary hormone approaches,
such as abiraterone, with immunomodulatory
agents such as sipuleucel-T is rational and the
source of ongoing investigation. Aiming to
capitalize on the survival benefit of both
abiraterone and sipuleucel-T, and provide
patients with a tangible positive effect in
terms of response and PFS, a randomized
phase II study is underway investigating
concurrent versus sequential use of abiraterone
acetate/prednisone and sipuleucel-T
(ClinicalTrials.gov identifier: NCT01431391). A
relevant question with this combination is
whether the concomitant steroids given as
standard to prevent abiraterone acetate-
induced ME will dampen the immune
response to sipuleucel-T. Data presented at
ASCO 2013 suggested that steroids did not
diminish the immune system response to
sipuleucel-T, but this conclusion awaits
validation [72].
Another mechanism of resistance may be
upregulation of programmed death 1 ligand
(PD-L1) induced by androgen blockade (C.
Drake, Johns Hopkins University: personal
communication). Ongoing studies are
evaluating the mechanism and timing of PD-
L1 upregulation in response to androgen
ablation. Combination therapy directed at
targeting both hormonal dependence with
agents, such as abiraterone acetate, and
resistance pathways, such as PD-1 or cytotoxic
T-lymphocyte antigen-4 (CTLA-4), could be
synergistic. A trial evaluating abiraterone
acetate with CTLA-blockade with ipilimumab
is ongoing in CRPC (ClinicalTrials.gov
identifier: NCT01688492).
Finally, as several of the prior studies have
shown, approximately 25% of patients have
primary abiraterone acetate resistance,
highlighting the need for the identification of
predictive markers and signatures that can
better characterize these patients a priori, and
direct them to more rational therapeutics or
clinical trials. Efforts to counteract resistance
mechanisms to abiraterone include
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combination strategies with c-MET blockade,
heat shock protein inhibitors, or histone
deacetylase inhibitors aimed at disrupting the
AR transcription complex. For example,
Sweeney and colleagues at the Dana-Farber
Cancer Institute are evaluating abiraterone
acetate in combination with cabozantinib, an
oral c-Met and vascular endothelial growth
factor receptor multi-tyrosine kinase inhibitor
(ClinicalTrials.gov # NCT01574937), an agent,
which has shown promising and unexpected
efficacy in bony metastases, as well as




The last several years have engendered
tremendous optimism for the treatment of
advanced prostate cancer. Patients now have
access to more than five therapies that prolong
survival, with several more on the horizon.
These much-needed advances in survival are
perhaps best demonstrated by the placebo arm
of the chemotherapy-naı¨ve, phase III
abiraterone acetate trial, where patients had a
median OS of 27 months, an increase from
18 months in the docetaxel era [9, 17]. While
both cohorts of patients received steroids,
which have some activity, and there has also
likely been an inherent shift to initiating
therapy earlier, this approximately 10-month
improvement in median OS is more likely the
consequence of the increased availability and
sequential use of multiple survival-improving
therapies, which patients on these trials had
access to after unblinding [9]. Tolerable,
effective agents, such as abiraterone acetate,
are critical for improving survival while
maintaining quality of life. Abiraterone acetate
remains a valuable option post-chemotherapy,
but the FDA’s expanded indication to the
chemotherapy-naı¨ve setting addresses a critical
unmet need, and in the future, abiraterone
acetate is likely to be used predominantly prior
to chemotherapy. Abiraterone acetate delivers
clinically meaningful advantages in its oral
administration, favorable tolerability profile,
and high efficacy. Further optimization of its
use is being investigated with the use of lower
doses or no concurrent steroids, and without
concomitant gonadal suppression.
In addition to abiraterone acetate’s clinical
benefits, its development is noteworthy for
having confirmed the clinical importance of
intratumoral androgen synthesis, which may
promote therapeutic resistance, and also for
validating the principle that AR signaling
continues to drive disease progression after the
development of castration resistance [4, 9, 25].
Progress will require the identification of
predictive biomarkers and the development of
combination therapies that will enhance
abiraterone acetate’s efficacy and thwart
resistance pathways. Future study will address
whether its use concurrently or in sequence
with other highly effective agents, such as
enzalutamide or sipuleucel-T, will result in
synergistic effects, and whether, as is currently
done with leuprolide acetate, abiraterone
acetate should be continued past progression.
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